About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
BOARD MEETINGS
Board
Meetings
Biogen Pharmachem Industries Ltd.
From Date
:
To Date
:
Source Date
Board Meeting Date
Details
24-Feb-2026
23-Mar-2026
Bonus issue
03-Feb-2026
11-Feb-2026
Quarterly Results
19-Jan-2026
03-Feb-2026
Quarterly Results(Cancelled) (Cancelled)
30-Oct-2025
07-Nov-2025
Quarterly Results
16-Jul-2025
23-Jul-2025
Quarterly Results
12-May-2025
23-May-2025
Audited Results
22-Jan-2025
05-Feb-2025
Quarterly Results & Inter alia, to consider and approve:- 1.) To approve and take on record the Un-Audited Financia l Results of the Company for the quarter ended on 31st December 2024. 2.) To approve and consider the appointment of Mr. Kelash Bunkar as Whole time Director and Chief Financial Officer of the Company. 3.) To consider the resignation of Mr. Niraj Vaghela from designation of Whole time Director and Chief Financial Officer of the Company. 4.)To approve and consider the appointment of Mr. Aman Patel as Director of the Company. 5.) To consider the resignation of Ms. Komal Chauhan from directorship of the Company. 6.) Any other matter with the permission of the board which the Board may think fit.
15-Oct-2024
13-Nov-2024
Quarterly Results
09-Aug-2024
13-Aug-2024
Preferential Issue of shares (Revised)
01-Aug-2024
09-Aug-2024
Preferential Issue of shares
25-Jul-2024
01-Aug-2024
Quarterly Results
16-May-2024
25-May-2024
Audited Results
16-Jan-2024
22-Jan-2024
Quarterly Results
03-Jan-2024
09-Jan-2024
Inter alia, to consider the appointment and Resignation of Director.
26-Oct-2023
01-Nov-2023
Quarterly Results
03-Aug-2023
10-Aug-2023
Quarterly Results
02-May-2023
08-May-2023
Audited Results
27-Jan-2023
02-Feb-2023
Quarterly Results
04-Nov-2022
11-Nov-2022
Quarterly Results
28-Jul-2022
03-Aug-2022
Quarterly Results
Page
1
of
5
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Smart ODR Portal
|
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
|
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
|
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
|
Details of Research Analyst
|
UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.